重症複合免疫不全症診断市場 - 世界の産業規模、シェア、動向、疾患タイプ別、検査タイプ別（TREC、全血球算定、遺伝子検査、生化学検査、その他）、エンドユーザー別、地域別、競合別、2020年～2030年

重症複合免疫不全症（SCID）診断の世界市場は、2024年に1億8,260万米ドルと評価され、2030年までのCAGRは9.20%で、予測期間中に目覚ましい成長を遂げると予測されています。

重症複合免疫不全症（SCID）は、免疫系に影響を及ぼすまれで重篤な遺伝性疾患であり、感染症に非常にかかりやすいです。SCIDはバブルボーイ病と呼ばれることが多いですが、これはこの疾患の患者が病原体への曝露を避けるために無菌環境で生活していたことに由来します。SCIDは細胞性免疫と体液性免疫の両方に重大な欠損をもたらします。つまり、罹患者はT細胞の機能（細胞性免疫）が著しく損なわれ、抗体を産生するB細胞の機能（液性免疫）を欠くことが多いです。重要な免疫細胞の欠如または機能不全により、SCID患者は細菌、ウイルス、真菌、寄生虫を含む様々な感染症に対して極めて脆弱です。これらの感染症は再発を繰り返し、重症化し、生命を脅かすこともあります。SCIDの症状は、母親の抗体が低下する生後数ヵ月に現れることが多いです。SCIDを発症した乳児は、治療に反応しない持続性の重症感染症を経験することがあります。

市場概要
予測期間	2026年～2030年
市場規模：2024年	1億8,260万米ドル
市場規模：2030年	3億719万米ドル
CAGR：2025年～2030年	9.20%
急成長セグメント	病院
最大市場	北米

主要な市場促進要因

SCID罹患率の上昇

主要な市場課題

遺伝的不均一性

主要市場動向

患者の支持と認識

目次

第1章 製品概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 重症複合免疫不全症（SCID）診断の世界市場の展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 疾患タイプ別（X連鎖SCID、ADA-SCID、その他）
  • 検査タイプ別（TREC、全血球数（CBC）、遺伝子検査、生化学検査、その他）
  • エンドユーザー別（病院、診断・研究機関、その他）
  • 地域別
  • 企業別（2024年）
• 市場マップ

第6章 アジア太平洋の重症複合免疫不全症（SCID）診断市場の展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の重症複合免疫不全症（SCID）診断市場の展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の重症複合免疫不全症（SCID）診断市場の展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の重症複合免疫不全症（SCID）診断市場の展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの重症複合免疫不全症（SCID）診断市場の展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の重症複合免疫不全症（SCID）診断市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• ARCHIMED SAS
• PerkinElmer LAS Inc.
• Health Research, Inc
• Winfertility, Inc.
• Portea Medical
• LaCAR MDX Technologies
• Labsystems Diagnostics Oy
• Devyser Diagnostics AB
• Leadiant Biosciences Inc.
• Revcovi

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Severe Combined Immunodeficiency (SCID) Diagnosis Market was valued at USD 182.60 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 9.20% through 2030. Severe Combined Immunodeficiency (SCID) is a rare and severe genetic disorder that affects the immune system, leaving individuals highly susceptible to infections. SCID is often referred to as the bubble boy disease, as individuals with this condition used to live in sterile environments to avoid exposure to pathogens. SCID results in a profound deficiency in both cellular and humoral immunity. This means that affected individuals have severely impaired T cell function (cellular immunity) and often lack functional B cells, which are responsible for producing antibodies (humoral immunity). Due to the absence or dysfunction of critical immune cells, individuals with SCID are extremely vulnerable to a wide range of infections, including bacterial, viral, fungal, and parasitic infections. These infections can be recurrent, severe, and life-threatening. Symptoms of SCID often appear in the first few months of life, as maternal antibodies wane. Infants with SCID may experience persistent, severe infections that do not respond well to treatment.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 182.60 Million
Market Size 2030	USD 307.19 Million
CAGR 2025-2030	9.20%
Fastest Growing Segment	Hospitals
Largest Market	North America

Key Market Drivers

Rising Incidence of SCID

Efforts to increase awareness and education among healthcare professionals and the public have led to more cases of SCID being identified and diagnosed. For instance, When federal health officials added severe combined immunodeficiency (SCID) to the Recommended Uniform Screening Panel (RUSP), a national guideline for newborn screening (NBS), in 2010, it remained unclear to what degree NBS would improve outcomes for babies diagnosed with SCID. Thirteen years later, a paper by the Primary Immune Deficiency Treatment Consortium (PIDTC) reveals that SCID identified through NBS increases overall survival for babies born with the condition. Babies with SCID lack a functioning immune system, making them vulnerable to fatal infections unless they are treated in infancy with a bone marrow transplant (BMT), also known as hematopoietic stem cell transplantation (HSCT), or clinical trial gene therapy. The new study from PIDTC is a retrospective analysis examining how various factors affected the survival of patients diagnosed with SCID across almost four decades. The paper focuses in particular on how the institution of population-based NBS impacted survival. In a study of 902 patients treated with BMT at 34 PIDTC centers, researchers examined data from several time periods beginning in 1982. They found that for the first three time periods, covering 28 years total, the five-year survival rate of SCID patients treated with BMT hovered at 72-73%. However, in the period from 2010-2018, corresponding to when states instituted NBS for SCID, five-year survival rose to 87%.

Key Market Challenges

Genetic Heterogeneity

SCID is not a single disorder but a group of rare genetic conditions, each caused by specific mutations in different genes. These mutations can affect various aspects of immune system development and function. As a result, there is a wide range of genetic mutations associated with SCID. Due to genetic heterogeneity, SCID is classified into multiple subtypes, each with distinct genetic causes. Common SCID subtypes include X-linked SCID, ADA-SCID, IL7R-SCID, and more. Accurate diagnosis requires identifying the specific genetic mutation responsible for the individual's condition. Diagnosing SCID involves a complex diagnostic process that includes clinical evaluation, immunological assays, and genetic testing. Genetic testing is often required to confirm the diagnosis and subtype, but selecting the appropriate genetic tests can be challenging due to the diversity of SCID-related genes. New, previously unidentified genetic mutations associated with SCID continue to be discovered through research. Identifying novel mutations adds complexity to diagnostic testing, as genetic tests must be updated to include these new variants. Some genetic tests for SCID may not cover the full spectrum of known SCID-related genes or mutations. This can result in a diagnostic gap, as certain mutations may be missed in standard testing panels. Genetic heterogeneity can lead to variability in the clinical presentation and severity of SCID. Two individuals with the same genetic subtype of SCID may exhibit different symptoms and clinical courses. This variability can complicate diagnosis and treatment planning. Genetic counseling is essential for families affected by SCID. The presence of various genetic mutations and subtypes can make genetic counseling complex, requiring a comprehensive understanding of the genetic basis of the condition.

Key Market Trends

Patient Advocacy and Awareness

Patient advocacy groups and organizations dedicated to SCID, such as the Immune Deficiency Foundation (IDF) and the SCID Angels for Life Foundation, play a crucial role in advocating for individuals and families affected by SCID. They provide support, resources, and a platform for raising awareness. Patient advocacy groups often work with policymakers to advocate for improved access to diagnostic testing, treatment, and research funding for SCID. They play a role in shaping healthcare policies related to rare diseases like SCID. Patient advocacy efforts can lead to increased research funding for SCID, driving advancements in diagnostic methods, treatments, and the understanding of the condition. Advocacy efforts have contributed to the inclusion of SCID in newborn screening programs in several regions. This has dramatically increased awareness about the importance of early diagnosis. Awareness campaigns target healthcare providers, including pediatricians and neonatologists, to ensure they recognize the signs and symptoms of SCID and refer infants for diagnostic testing. Public awareness campaigns, often initiated by patient advocacy groups, aim to educate the general population about SCID. These campaigns may include social media outreach, educational materials, and community events. Events like the International SCID Awareness Day, held on October 15th each year, help raise global awareness about the condition. It is an opportunity for patients, families, healthcare providers, and advocates to come together to educate the public. SCID cases that receive media coverage, such as documentaries or news stories, can significantly increase awareness and prompt individuals to seek diagnostic testing if they suspect SCID in their families.

Key Market Players

• ARCHIMED SAS
• PerkinElmer LAS Inc
• Health Research, Inc
• Winfertility Inc.
• Portea Medical
• LaCAR MDX Technologies
• Labsystems Diagnostics Oy
• Devyser Diagnostics
• Revcovi
• Leadiant Biosciences Inc.

Report Scope:

In this report, the Global Severe Combined Immunodeficiency (SCID) Diagnosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Severe Combined Immunodeficiency (SCID) Diagnosis Market, By Disease Type:

• X-linked SCID
• ADA-SCID
• others

Severe Combined Immunodeficiency (SCID) Diagnosis Market, By Test Type:

• TREC
• Complete blood count (CBC)
• Genetic Test
• Biochemical Test
• Others

Severe Combined Immunodeficiency (SCID) Diagnosis Market, By End-User:

• Hospitals
• Diagnostic and Research Laboratories
• Others

Severe Combined Immunodeficiency (SCID) Diagnosis Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Severe Combined Immunodeficiency (SCID) Diagnosis Market.

Available Customizations:

Global Severe Combined Immunodeficiency (SCID) Diagnosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (X-linked SCID, ADA-SCID, others)
  • 5.2.2. By Test Type (TREC, Complete blood count (CBC), Genetic Test, Biochemical Test, others)
  • 5.2.3. By End User (Hospitals, Diagnostic and Research Laboratories, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Test Type
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Test Type
      • 6.3.1.2.3. By End User
  • 6.3.2. India Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Test Type
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Test Type
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Disease Type
      • 6.3.4.2.2. By Test Type
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Disease Type
      • 6.3.5.2.2. By Test Type
      • 6.3.5.2.3. By End User

7. Europe Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Test Type
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Test Type
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Test Type
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Test Type
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Test Type
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Test Type
      • 7.3.5.2.3. By End User

8. North America Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Test Type
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Test Type
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Test Type
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Test Type
      • 8.3.3.2.3. By End User

9. South America Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Test Type
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Test Type
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Test Type
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Test Type
      • 9.3.3.2.3. By End User

10. Middle East and Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Test Type
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Test Type
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Test Type
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Severe Combined Immunodeficiency (SCID) Diagnosis Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Test Type
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Severe Combined Immunodeficiency (SCID) Diagnosis Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. ARCHIMED SAS
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. PerkinElmer LAS Inc.
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Health Research, Inc
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. Winfertility, Inc.
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. Portea Medical
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. LaCAR MDX Technologies
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Labsystems Diagnostics Oy
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Devyser Diagnostics AB
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Leadiant Biosciences Inc.
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10. Revcovi
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer